Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Regenicin, Inc. (RGIN)
Little Falls, NJ, US
Regenicin, Inc. is dedicated to the development and commercialization of advanced tissue-engineered skin replacement technologies. Its product line features NovaDerm, a sophisticated multi-layered living and cultured skin substitute engineered for treating burn injuries, alongside TempaDerm, which addresses more localized wound areas like ulcers. These innovative solutions aim to rejuvenate the characteristics of healthy human skin, finding application in burn therapy, chronic wound management, and various plastic surgery procedures. Incorporated in 2007 and based in Little Falls, New Jersey, the company was previously known as Windstar, Inc., adopting the Regenicin, Inc. name in July 2010.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +0.00% | +0.00% | +0.00% | +0.00% | +0.00% | +9,900.00% | +0.00% | -95.24% | -99.69% | -99.62% | -99.99% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
| Rating | 2024-11 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 0 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
-
Revenue growth Biotechnology: +1.6%—
-
EPS growth Biotechnology: +29.7%+6.3% Q1'23: -109.1% (vs Q1'22)
-
FCF margin FCF growth · Biotechnology: +16.2%—
-
EBIT margin Biotechnology: +0.0%—
-
ROIC Biotechnology: -16.1%— Q1'23: +7.5% (vs Q1'22)
-
Share dilution Biotechnology: -3.4%+0.0% ★ Q1'23: +0.0% (vs Q1'22)
-
Debt / EBITDA Net debt/EBITDA · Biotechnology: 0.16×-1.07× Q1'23: -0.49× (vs Q1'22)
Owner Earnings
Owner's Earnings history not available.
Ownership Overview
| # | Reporting person | Amount owned | % of class | Sole voting | Shared voting | Sole dispositive | Shared dispositive | Type | Citizenship | Filing date | SEC filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | 56-0939887 | 10.02M | 6.53% | 10.02M | — | 10.02M | — | — | North Carolina | 2022-03-17 | ↗ |
| 2 | HEALTH INSURANCE CO., LTD. | 10.00M | 6.51% | 10.00M | — | 10.00M | — | IC | North Carloina, USA | 2017-03-30 | ↗ |
| 3 | 58-1575035 | 10.00M | 6.50% | — | — | — | — | BK, HC | Georgia | 2019-02-14 | ↗ |
Institutional Activity (13F)
| # | Investor | Shares / Δ | Mkt value / Δ | Own% / Δ | Weight% / Δ | Avg px / Perf. | Hold / Status |
|---|---|---|---|---|---|---|---|
| 1 | WILLIAMS JONES WEALTH MANAGEMENT, LLC. | — -75.0K (-100.0%) | — -23.0 (-100.0%) | 0.00% -0.049 pp | 0.00% +0.000 pp | USD— | 5 qtrs SOLD |
ETF Ownership
This company is not held by any ETF in our universe.
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Randall E. McCoy | Chairman, Chief Executive Officer & President | 250.0K | male |
| J. Roy Nelson | Controller & Chief Science Officer | 150.0K | — |
| John J. Weber | Chief Financial Officer & Director | 125.0K | male |
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for RGIN
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
